Calidi Biotherapeutics, Inc.
CLDIStock
$0.12−98.24%52W
Market Cap$2.37M
P/E—
Div yield—
Beta1.36
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-98.07%
Price vs S&P 500 (4W)-24.34%
VGM Score5.26
Market Capitalization$2.37M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLDICalidi Biotherapeutics, Inc. | — | — | F | $0.12 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Calidi Biotherapeutics is a clinical-stage immuno-oncology company developing allogeneic stem cell therapies that deliver oncolytic viruses to treat cancer. Its pipeline includes CLD-101 for high-grade gliomas, CLD-201 for solid tumors, and CLD-400 for lung cancer and metastatic tumors, with CLD-301 in discovery research.